| Term 
 
        | T or F: When an organism is pathogenic it is also resistant. |  | Definition 
 
        | F: pathogenesis does NOT equal resistant. 
 Actually, because both require energy, they have an inverse relationship
 |  | 
        |  | 
        
        | Term 
 
        | What are two examples of an antigen or antibody test? |  | Definition 
 
        | Strep Test (Group A Streptococcus) Rapid HIV Test
 |  | 
        |  | 
        
        | Term 
 
        | How can the mecA of S.aureus be detected? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the MIC measuring |  | Definition 
 
        | The drug/organism interaction (simplest method) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Can't usually get a true MIC (only 1,2,4,8...) 
 Additionally, lab standards are MIC+/- 1 dilution (so if says MIC = 4, could be anywhere between 2 and 8)
 |  | 
        |  | 
        
        | Term 
 
        | How do you measure the MBC? |  | Definition 
 
        | on agar plate (kills 99.9% of germs) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Strip with different concentrations of antibiotic placed on agar plate - zone of inhibition forms when bacteria is susceptible 
 Can get MIC by looking at lowest drug concentration it is susceptible to.
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Multiple discs with antibiotics placed on agar plate with bacteria. Zone of inhibition around each antibiotic bacteria is susceptible to (~1 mm) 
 Doesn't give an actual MIC
 |  | 
        |  | 
        
        | Term 
 
        | Which is worse, giving an antibiotic because the patient was thought to be susceptible and really wasn't, or not giving an antibiotic because they thought the patient was resistant? |  | Definition 
 
        | Giving an antibiotic to which the patient is actually resistant (still not getting adequate treatment) 
 if didnt give them an antibiotic that was falsely read as resistant, then most likely still got an antibiotic that works for them
 |  | 
        |  | 
        
        | Term 
 
        | T or F: FQs can be used for Pseudomonas? |  | Definition 
 
        | F - even though the lab results will come back saying it is susceptible, it is not. 
 Never use a fluoroquinolone ALONE for Pseudomonas
 |  | 
        |  | 
        
        | Term 
 
        | Vancomycin/MRSA MIC comes back as 2, what could be an issue? |  | Definition 
 
        | Resistance. Even though MIC of 2 is seen as susceptible (breakpoint) resistance is increasing so may need drug in greater concentrations 
 if MIC>2 for S.aureus, use alternative agent
 |  | 
        |  | 
        
        | Term 
 
        | What is an instance in which the lab reports that Klebsiella (or other enterobacteriaceae) is susceptible to a certain antibiotic, but when used treatment fails? |  | Definition 
 
        | When the bacteria is an ESBL producer and a penicillin is used - ESBLs get induced. |  | 
        |  | 
        
        | Term 
 
        | When reading an antibiogram, the number that is reported is the susceptible or resistant population? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is selection pressure? |  | Definition 
 
        | (Think Natural Selection) 
 The idea that the resistant bacterium will live and multiply and others will die (vertical resistance)
 |  | 
        |  | 
        
        | Term 
 
        | What are the most common plasmid-mediated beta-lactamases in gram negative bacteria? 
 What drugs are stable in their presence?
 |  | Definition 
 
        | TEM-1, TEM-2, SHV-1 
 Extended-spectrum ceph (2nd/3rd)
 beta-lactams + beta-lactamase inhibitors
 Carbapenems
 |  | 
        |  | 
        
        | Term 
 
        | What beta-lactams are stable in the presence of ESBLs |  | Definition 
 
        | Carbapenems Clavulanic acid
 |  | 
        |  | 
        
        | Term 
 
        | How do we screen for ESBL producers? |  | Definition 
 
        | If MIC> or = 2mcg/mL to ceftazidime, cefotaxime, or ceftriaxone then do an ESBL confirmatory test 
 (Test the drug with clavulanic acid - if the organism then presents as susceptible (having 3+ decreases in MIC read) the organism is an ESBL producer
 
 Must report as resistant to ALL cephalosporins and penicillins
 |  | 
        |  | 
        
        | Term 
 
        | What is the DOC for ESBL producing organisms? |  | Definition 
 
        | Carbapenem 
 
 **Amox/Clav Acid cant be used in high enough concentration to be therapeutic
 Alt: Cefepime - still treatment failures
 Tigecycline
 Other drug that is susceptible
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NOT inhibited by beta-lactamase inhibitors (clavulanic acid) 
 Chromosomal and Inducible
 
 Produced by the SPACE bacteria (nosocomial pathogens)
 
 'stably de-repressed' - there is no repression, always turned on
 |  | 
        |  | 
        
        | Term 
 
        | 2 DOC for AmpC beta-lactamase producers |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Issue with culturing a patient who has a bacteria with the Amp-C gene |  | Definition 
 
        | Stable de-repression - will appear to be susceptible upon initial testing, but then treating with the drug will induce beta-lactamase production - will be seen as resistant 3 days later. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Two types: serine beta-lactamases and metallo-beta-lactamases (MBL) 
 chromosomally or plasmid encoded
 
 Can lead to resistance in carbapenems and anti-pseudomonal cephalosporin/penicillins
 |  | 
        |  | 
        
        | Term 
 
        | Treatment of carbapenemase producers |  | Definition 
 
        | Polymyxin B + rifampin or imipenem 
 Tigecycline
 
 Aminoglycosides
 |  | 
        |  | 
        
        | Term 
 
        | What is gene that causes the replacement of PBP2 with PBP2a? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the only beta-lactam that can target PBP2a? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Penicillin resistance in what organisms is associated with 4 PBPs? |  | Definition 
 
        | Strep. pneumoniae 
 in resistant to PCN, then increased macrolide resistance, BUT FQ resistance still low
 |  | 
        |  | 
        
        | Term 
 
        | Which gene carries clindamycin inducible resistance? How can the lab screen for this? |  | Definition 
 
        | erm gene 
 Disc Diffusion Test (D Test)
 |  | 
        |  | 
        
        | Term 
 
        | Which organism has the highest incidence of changing the bacterial target site against vancomycin (change to D-ala-D-lac or D-ala-D-ser) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the VanA and VanB genes? |  | Definition 
 
        | Genes that change the target site of penicillin to: A: D-ala-D-lac
 B: D-ala-D-ser
 |  | 
        |  | 
        
        | Term 
 
        | When MRSA acquires the VanA gene it is considered _______. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What PD parameter correlates to efficacy in vancomycin dosing? |  | Definition 
 
        | AUC/MIC 
 Target AUC/MIC is greater than 400
 -to achieve, trough target = 15-20 mcg/mL
 |  | 
        |  | 
        
        | Term 
 
        | What is a major mechanism of resistance against Tetracyclines? |  | Definition 
 
        | Efflux pumps 
 tet genes
 
 NOTE: tigecycline has steric hindrance and is not a substrate for these pumps (why broader spectrum)
 |  | 
        |  | 
        
        | Term 
 
        | T or F: tigecycline can be used to treat all common infections |  | Definition 
 
        | F - very broad spectrum but doesnt cover Pseudomonas |  | 
        |  | 
        
        | Term 
 
        | T or F: bacteria can have more that one mechanism of resistance. |  | Definition 
 
        | T: ex, meropenem and Psuedomonas/Acinetobacter ->up-regulation of efflux pump gene and loss of porin channel protein are both required for resistance to be noted |  | 
        |  | 
        
        | Term 
 
        | If someone has a drug hypersensitivity then they have a drug allergy - T or F. |  | Definition 
 
        | F: if someone has a drug hypersensitivity it can be allergic or non-allergic hypersensitivity |  | 
        |  | 
        
        | Term 
 
        | Risk factors for having an allergy |  | Definition 
 
        | Genetic factors Concurrent medical illness (Ebstein-Barr Virus, HIV, asthma)
 Previous drug reaction
 Multiple allergy syndrome
 The nature of the drug (its interaction with the immune system, dose, duration, route, cross-sensitization)
 |  | 
        |  | 
        
        | Term 
 
        | Mechanism of a Type I hypersensitivity reaction |  | Definition 
 
        | IgE mediated triggers the release of histamine
 
 manifests as urticaria, angioedema, anaphylaxia/shock, bronchial asthma
 |  | 
        |  | 
        
        | Term 
 
        | Type II and III hypersensitivity reactions mechanism and presentation |  | Definition 
 
        | Antibody, immune-complex, or phagocyte-mediated 
 presents as:
 Immune hemolytic anemia
 Thrombocytopenia
 Blood cell dyscrasias
 Organ-specific reactions
 |  | 
        |  | 
        
        | Term 
 
        | What is the mechanism and presentation of Type IV hypersensitivity |  | Definition 
 
        | T cell mediated Delayed Rashes: maculopapular exanthema, SJS/TEN, delayed urticaria, eczema Organ-specific reactions |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A chemically non-reactive drug that becomes reactive (to the immune system) upon metabolism 
 Potent and rapid intracellular detoxification of the hapten can prevent immunogenicity elsewhere in the body, but can cause an organ-specific reaction (liver-hepatitis or kidney-interstitial nephritis)
 -Ex: GSH - depletion of glutathione in HIV patients
 |  | 
        |  | 
        
        | Term 
 
        | Does a hapten cause a Type I, II, III, or IV reaction? |  | Definition 
 
        | Could cause any 
 Depends on:
 1. Where it binds (surface vs soluble)
 2. What binds it (IgE, IgG, T cells)
 |  | 
        |  | 
        
        | Term 
 
        | If patient presents with urticaria after first exposure to a drug, how will they present if they are exposed a second time? |  | Definition 
 
        | There is no way to know, they could just get urticaria again or they could progress to angioedema or worse |  | 
        |  | 
        
        | Term 
 
        | Urticaria presentation and mechanism |  | Definition 
 
        | wheal and flare rxn (IgE) -increased vascular permeability (small venules)
 -mast cells and basophils release histamine, eicosanoids
 -cutaneous neurons release neuropeptides (axon reflex)
 
 Skin swells and itches
 
 No mucus membrane involvement
 |  | 
        |  | 
        
        | Term 
 
        | Angioedema presentation and mechanism |  | Definition 
 
        | well-demarcated non-pitting edema 
 rxn deeper in dermis and SQ tissue than urticaria
 
 Usually face, tongue, lips, eyelids
 Can get respiratory distress
 
 GET PATIENT SEEN
 |  | 
        |  | 
        
        | Term 
 
        | T or F: even though IgE mediated reactions usually occur within 1-2 hours and T-cell mediated reactions usually take 2 hr-10 days, timing doesn't always go by the book. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Stevens Johnson Syndrome (SJS) and Toxic Epidermis Necrolysis (TEN) |  | Definition 
 
        | Fever, sore throat, cough, eye burning 
 facial swelling, target lesions, skin pain, red/purple rash, blistering (skin and mucous membranes), sloughing of skin
 Nikolskys sign - scratch skin and epidermis comes off
 
 Usual causes: Sulfa, PCNs, NSAIDs, anticonvulsants, infections
 
 Treat like a burn patient
 |  | 
        |  | 
        
        | Term 
 
        | Maculopapular exanthem (MPE) and Bullous Exanthem |  | Definition 
 
        | higher activation of circulating T Cells 
 MPE: CD4 (only certain MHC-II cells)
 Bullous: CD8 (all cells)- more reaction [why they look fused together]
 |  | 
        |  | 
        
        | Term 
 
        | What should be done if a patient presents with a delayed hypersensitivity reaction? |  | Definition 
 
        | Stop all ongoing antibiotics 
 Do liver, renal, and blood tests
 |  | 
        |  | 
        
        | Term 
 
        | What is the most likely cause of a small petechiael rash? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the most likely agent being used when someone with an Epstein-Barr viral infection presents with maculopapular exanthem |  | Definition 
 
        | Aminopenicillins (amoxicillin/ampicillin) |  | 
        |  | 
        
        | Term 
 
        | With what drug are HIV-patients most likely to have an increased risk of an allergic reaction? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are some lab (serology) tests that could be used to confirm a drug allergy? |  | Definition 
 
        | Immediate reactions: 1. serum tryptase
 2. serum histamine
 
 Delayed reactions
 3. CBC: eosinophilia and lymphocytosis, leukocytosis
 4. Liver function tests: increased ALT, AST, ALP
 5. Serum creatinine: increased = +
 6. Urine microscopy and dipstick: nephritis, proteinuria
 7. CRP: can increase or decrease = sign of inflammation
 |  | 
        |  | 
        
        | Term 
 
        | When is the skin prick or intradermal test used for drug allergies |  | Definition 
 
        | use to deterimine if reaction is IgE mediated |  | 
        |  | 
        
        | Term 
 
        | Skin prick test: time, sensitivity, and specificity |  | Definition 
 
        | 15-20 minutes 
 Specific and fairly sensitive
 |  | 
        |  | 
        
        | Term 
 
        | Intradermal skin test: when indicated and sensitivity and specificity |  | Definition 
 
        | Do it when skin prick test is negative and allergen is highly suspect 
 more sensitive than skin prick test
 may induce false positive reactions (less specific)
 
 May induce systemic reactions
 |  | 
        |  | 
        
        | Term 
 
        | What is drug provocation tests and when should it be used |  | Definition 
 
        | Give a drug and monitor patients for allergic reaction 
 Indications:
 1. Exclude hypersensitivity in non-suggestive history
 2. Utilize structurally similar drugs in proven hypersensitivity (ex: want to use cephalexin in an penicillin allergic patient)
 3. Definitive diagnosis in suggestive history with negative, non-conclusive or non-available tests
 
 DO NOT USE IF:
 1. pregnant
 2. a co-morbidity exists where DPT can provoke a situation beyond medical control (ex: acute infection, uncontrolled asthma, cardiac disease, brittle)
 3. immunobullous drug eruptions
 4. severe systemic initial reactions (SJS)
 
 Must explain risk vs benefit to patient (informed consent)
 Ideal to: d/c antihistamines (3 days short acting and 7 days long acting); fasted overnight
 careful observation and resuscitation equipment available
 |  | 
        |  | 
        
        | Term 
 
        | When to desensitize a patient |  | Definition 
 
        | When there is no reasonable alternative -NOTE: if anaphylaxis originally it is NOT contraindicated, but if the patient had SJS/TEN do NOT do desensitization
 
 **Patient will still be considered allergic to the drug
 |  | 
        |  | 
        
        | Term 
 
        | How to desensitize a patient |  | Definition 
 
        | Must be done by a physician (ICU preferred) d/c all beta-adrenergic antagonists (including ophthalmics)
 do NOT premedicate with corticosteroids/antihistamines (For some drugs, premedication is recommended - FQ, vanco)
 monitor with ECG
 
 Start low (can be oral or parenteral)
 Double dose every 20-30 min until reach target
 
 If skip a dose, must start all over
 If patient has transient allergic reaction - dont stop treatment
 |  | 
        |  | 
        
        | Term 
 
        | Possible mechanisms of desensitization |  | Definition 
 
        | IgE mediated reactions 
 Consumption of IgE in immune complexes
 Mediator depletion from mast cells and basophils
 Antigen specific mast cell desensitization
 |  | 
        |  | 
        
        | Term 
 
        | Cross-reactivity between penicillins and cephalosporins |  | Definition 
 
        | more common with type I reactions IgE mediated reaction to PCNs is 10% cross-reactivity to ceph (esp. 1st gen)
 
 If reactive to ceph but not pcn - there is a higher incidence of ceph cross-reactivity among drugs with similar R1 side chains
 -Ceftriaxone = cefotaxime = cefepime
 -Cefuroxime = ceftazidime
 
 Low rate of cross-reactivity between PCN and carbapenems
 
 NO cross-reactivity with aztreonam
 |  | 
        |  | 
        
        | Term 
 
        | Up to 50% of HIV patients have an allergy to what medication? |  | Definition 
 
        | sulfonamides 
 SMX can be a hapten (able to cause all forms of drug allergies)
 |  | 
        |  | 
        
        | Term 
 
        | T or F: if you are allergic to one fluoroquinolone you are considered allergic to all of them |  | Definition 
 
        | There is cross reactivity, so: 
 if an immediate hypersensitivity - must chose different drug
 
 if delayed hypersensitivity can challenge and desensitize
 |  | 
        |  | 
        
        | Term 
 
        | How to decide to treat a drug allergy as inpatient or outpatient |  | Definition 
 
        | Inpatient: observation, skin care, I/V, allergist referral -Chose if: angioedema, severe skin (ex: SJS), systemic symptoms (fever, lymphadenopathy), possibly >1 implicated drug
 
 Outpatient: treat if urticaria/maculopapular rash, fixed drug erruption, no systemic symptoms
 
 Refer to allergist if: uncertain cause or if uncertain allergy
 |  | 
        |  | 
        
        | Term 
 
        | Treatment of a drug allergy |  | Definition 
 
        | stop suspected drug(s) 
 Resuscitation (CPR in anaphylaxis)
 
 Give:
 Antihistamines (IV or PO)
 IM epinephrine for anaphylaxis
 Systemic corticosteroids for DiHS, SJS
 High dose IVIG for early TEN/SJS
 
 Emollients and skin care
 Hydration and prevention of skin superinfections (TEN)
 |  | 
        |  | 
        
        | Term 
 
        | What is another name for an upper UTI? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What constitutes an uncomplicated (vs a complicated) UTI |  | Definition 
 
        | Uncomplicated: otherwise healthy female ages 15-45) 
 Complicated: men; lesions, obstruction, neurologic dysfunction (cant void completely), upper and lower tract
 |  | 
        |  | 
        
        | Term 
 
        | What are the two types of recurrent UTIs |  | Definition 
 
        | 3+ UTIs in 1 year in healthy, NONpregnany women 
 Reinfection: different organism (>2 weeks apart)
 Relapse: same organism, persistent sourse of infection (stones, catheter) (<2 weeks apart)
 |  | 
        |  | 
        
        | Term 
 
        | If there is non urinary pain, but UA comes back positive for bacteria, does the patient have a UTI? |  | Definition 
 
        | No, asymptomatic bacteriuria |  | 
        |  | 
        
        | Term 
 
        | T or F: you can only rule out a lower UTI, you cant really rule out an upper UTI |  | Definition 
 
        | T 
 usually if no symptoms then no UTI
 |  | 
        |  | 
        
        | Term 
 
        | Clinical presentation of a UTI (upper vs lower) |  | Definition 
 
        | Lower: DYSURIA, urgency, nocturia, suprapubic heaviness, hematuria, foul-smelling 
 Upper: FLANK PAIN, fever, N/V, malaise, muscle weakness
 
 Elderly: mental status changes
 |  | 
        |  | 
        
        | Term 
 
        | Typical lab diagnosis of a UTI |  | Definition 
 
        | UA: clarity is cloudy
 Color: orange/red (blood)
 pH: increased (normally acidic)
 WBC or RBC may be present
 Leukocyte esterase may be present (breakdown of WBC)
 nitrite (gram negative bacterial metabolite)
 Organisms present - lower threshold amount for men than for women
 
 Urine culture (NOTE UA does not culture anything in urine - just quantifies how much is present)
 
 CBC (done if UTI severe or worsens)
 |  | 
        |  | 
        
        | Term 
 
        | What is the most common pathogen found in UTIs |  | Definition 
 
        | E.coli 
 (Proteus, Klebsiella, Staphylococci, saprophyticus, other)
 |  | 
        |  | 
        
        | Term 
 
        | What are two drug classes that have been used to treat UTIs that cause A LOT of collateral damage |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are some options for the treatment of UTIs |  | Definition 
 
        | 1. Nitrofurantoin monhydrate/macrocrystals Make sure patient has adequate renal function to make sure drug gets there and to avoid toxicity
 
 SMX-TMP: DS BID x3 days
 
 Fosfomycin 3 gm once
 -minimal resistance/collateral damage; inferior efficacy
 
 Augmentin or PO cephalosporins
 
 Cipro/levo: 3 days is usually sufficient
 -reserve for more serious infections because of collateral damage (and growing resistance)
 |  | 
        |  | 
        
        | Term 
 
        | If patient presents with pyelonephritis what is the first thing you should do? |  | Definition 
 
        | get a urine culture BEFORE starting antibiotics |  | 
        |  | 
        
        | Term 
 
        | How do you decide to treat pyelonephritis inpatient or outpatient? |  | Definition 
 
        | Inpatient: pregnancy, diabetes, immunocompromised, structural abnormalities 
 treat with IV (at first) if inpatient because of big risk of N/V with most abx
 |  | 
        |  | 
        
        | Term 
 
        | Treatments for pyelonephritis |  | Definition 
 
        | Can start PO regimens with IV x 24h or until hemodynamically stable 
 IV/PO cipro/levofloxacin (7-10 days)
 
 IV extended spectrum beta-lactam +/- aminoglycoside
 
 PO beta-lactams (cephalosporins>augmentin b/c of resistance) x10-14days
 
 PO Bactrim x 14 days (only if susceptible)
 |  | 
        |  | 
        
        | Term 
 
        | Should you treat asymptomatic bacteruria |  | Definition 
 
        | No, except for: 
 1. pregnant women (b/c development issues associated with bacteria in urine)
 2. Children <5 yr (increased risk of long-term damage)
 3. Patients undergoing TURP or urologic procedure
 
 
 NOTE: recurrence is common and there is 100% incidence in patients with a catheter
 |  | 
        |  | 
        
        | Term 
 
        | T or F: pregnant women have more pyelonephritis |  | Definition 
 
        | T - they have higher incidence of acute pyelonephritis, but bacteriuria rates are equal in pregnant and non-pregnant women |  | 
        |  | 
        
        | Term 
 
        | What do you use to treat UTIs in pregnancy and for how long |  | Definition 
 
        | Beta-lactams Sulfonamides
 Nitrofurantoin
 
 Use for ~7 days
 |  | 
        |  | 
        
        | Term 
 
        | Why should you treat a UTI in pregnancy? |  | Definition 
 
        | They are associated with significant morbidity for mom and baby 
 prematurity, low birth weight, still birth
 |  | 
        |  | 
        
        | Term 
 
        | What are some risk factors for UTI recurrence? |  | Definition 
 
        | sexual intercourse diaphragm or spermicide use
 |  | 
        |  | 
        
        | Term 
 
        | How to treat recurrent UTIs |  | Definition 
 
        | If sex related: post-coital voiding and single dose bactrim 
 If no precipitating event:
 -6 month therapy
 -Bactrim, FQ, macrobid
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | >101 F >100.4 x 2 readings >1 hr apart |  | 
        |  | 
        
        | Term 
 
        | What is a common species of staph that is referred to as 'coag. negative staph?' |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What patient population is candiduria commonly seen in? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Who should be treated for candiduria? |  | Definition 
 
        | ONLY treat symptomatic or high-risk patients 
 Neutropenic, neonates, urologic prodecure
 |  | 
        |  | 
        
        | Term 
 
        | How should candiduria be treated? |  | Definition 
 
        | CHANGE THE CATHETER! 
 Fluconazole
 Amphotericin B IV
 Amp B bladder irrigation (irritating)
 
 7-14 days
 |  | 
        |  | 
        
        | Term 
 
        | What is the major difference between the treatment of UTIs and prostatitis? |  | Definition 
 
        | Duration of treatment 
 UTI: up to 2 weeks
 Prostatitis: 4-6 weeks
 |  | 
        |  | 
        
        | Term 
 
        | What can cause prostatitis? |  | Definition 
 
        | Identified by presence of bacteria and inflammatory cells 
 causes:
 -reflux of urine into prostate
 -sex
 -functional abnormalities of prostate
 -catheters
 -urinary tract procedures
 
 Bacterial causes similar to UTIs (E.coli)
 |  | 
        |  | 
        
        | Term 
 
        | Treatments for prostatitis |  | Definition 
 
        | FQ (most common) Bactrim
 (Cephalosporins and Zosyn)
 
 4-6 weeks
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | the ability of a test to identify positive results in patients who actually have the disease (true positive rate) Higher sensitivity = lower chance of false negative High sensitivity is preferred when the consequences of not identifying the disease are serious (ex: cancer screenings) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | the percent of negative results in people without the disease (true negative rate) Higher specificity = less chance of a false positive Good for confirming a diagnosis because the tests are rarely positive in the absence of disease |  | 
        |  | 
        
        | Term 
 
        | T or F: infections with any STD increases the risk of HIV acquisition. |  | Definition 
 
        | T - sores/inflammation can decrease the skin's ability to prevent infection |  | 
        |  | 
        
        | Term 
 
        | What is the number one risk factor for getting an STD? |  | Definition 
 
        | Number of sexual partners 
 Others:
 Unprotected sex
 Social/Cultural factors
 Lower socioeconomic status
 Drug abuse (IV drug user)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which STDs are most painful |  | Definition 
 
        | Herpes HPV
 
 Both viruses are the most painful!
 |  | 
        |  | 
        
        | Term 
 
        | Which STDs present with sores and which present with drips? |  | Definition 
 
        | Sores: 1. Syphilis
 2. HSV (herpes)
 3. HPV
 **NOTE- these are the most painful and least painful
 
 Drips:
 1. Gonorrhea
 2. Chlamydia
 3. Trichomoniasis
 NOTE - all of these can present with or without discomfort
 |  | 
        |  | 
        
        | Term 
 
        | T or F: you can cure herpes? |  | Definition 
 
        | F - cant completely eradicate |  | 
        |  | 
        
        | Term 
 
        | What organism/virus causes gonorrhea? |  | Definition 
 
        | Neisseria gonorrhea 
 (G- diplococcus)
 |  | 
        |  | 
        
        | Term 
 
        | Presentation of Gonorrhea |  | Definition 
 
        | 50% females are asymptomatic 
 Sx: dysuria, urinary frequency, PURULENT DISCHARGE, rectal discharge, pharyngitis
 drips +/-discomfort
 
 NOTE: men are more likely to give it to women than vice versa
 |  | 
        |  | 
        
        | Term 
 
        | DOC for gonorrheal (uncomplicated) infection |  | Definition 
 
        | Ceftriaxone 250 mg IM once 
 (Cefixime and FQ were once recommended, but not any more because of increased resistance)
 
 + Drug for chlamydia
 |  | 
        |  | 
        
        | Term 
 
        | What two STDs are treated concurrently becuase they are often found together |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How to treat a disseminated gonorrheal infection (it has spread) |  | Definition 
 
        | Ceftriaxone 1 gm IM/IV Q24h ->duration not well defined (individualize) |  | 
        |  | 
        
        | Term 
 
        | What should you give to a pregnant women who presents with chlamydia? |  | Definition 
 
        | Azithromycin 1 g PO x1 dose 
 Erythromycin is an alternative
 
 (dont give a tetracycline because contraindicated in pregnancy)
 |  | 
        |  | 
        
        | Term 
 
        | What causes chlamydia, and what type of organism is it? |  | Definition 
 
        | C. trachomatis 
 obligate intracellular bacterial parasite
 -important because symptoms wont manifest until 1-3 weeks have past
 |  | 
        |  | 
        
        | Term 
 
        | What is the most frequently reported STD in the US? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Who is more likely to know they have an STD, a man or a woman? |  | Definition 
 
        | Man, because women are more likely to be asymptomatic in with most diseases (must be proactive and encourage screening) |  | 
        |  | 
        
        | Term 
 
        | What are the screening criteria for chlamydia? |  | Definition 
 
        | All sexually active females should be screened annually -Ages 20-25 (most common age group)
 -Multiple sex partners
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | urethral/cervical discharge -less profuse and more mucoid/watery compared to gonorrhea
 drips
 +/- discomfort
 
 Asymptomatic in 50% men and 66% women
 |  | 
        |  | 
        
        | Term 
 
        | What are the recommended treatment options for chlamydia and what are some alternatives? |  | Definition 
 
        | Recommended: 1. Azithromycin 1 gm PO once
 2. Doxycycline 100 mg PO BID x7
 
 Alternative
 1. Levofloxacin 500 mg QD x 7 days
 2. Erythromycin base 500 mg QID x 7 days
 
 **Azithromycin 2g PO x1 dose treats both Chlamydia and Gonorrhea (more GI issues, good if allergic to ceftriaxone)
 |  | 
        |  | 
        
        | Term 
 
        | How does Trichomoniasis uniquely present |  | Definition 
 
        | "Strawberry cervix" - cervical petechiae Discharge: frothy, gray to yellow-green malodorous
 
 Positive KOH "whiff" test
 
 motile flagellated protazoa, many WBCs
 
 Common among vaginal infections: itching, dysuria, discharge
 |  | 
        |  | 
        
        | Term 
 
        | Recommended treatment of trichomoniasis and some alternatives |  | Definition 
 
        | Recommended: 1. Metronidazole 2 gm PO x 1 dose
 2. Tinidazole 2 gm PO x 1 dose (esp if metro fails)
 
 Alternatives:
 Metronidazole 500 mg PO BID x 7 days (**Preferred if partner is NOT simultaneously treated - because is self-limiting in men after ~7 days)
 |  | 
        |  | 
        
        | Term 
 
        | T or F: Metronidazole gel is just as effective in treating trichomoniasis as the oral regimen |  | Definition 
 
        | F - only 50% as effective |  | 
        |  | 
        
        | Term 
 
        | What are the stages of Syphilis? |  | Definition 
 
        | Primary: single, painless indurated lesion (chancre) - eventually heals Secondary: rash +/- itching, mucocutaneous lesions, flu-like symptoms
 Latent: Asymptomatic
 Tertiary: CV (aortic insufficiency), neurosyphilis (meningitis, paresis, dementia), gummatous lesions SYSTEMIC (10-30 years)
 |  | 
        |  | 
        
        | Term 
 
        | What is the treatment of syphilis |  | Definition 
 
        | Primary/Secondary/Early latent (<1 year) Benzathine Pen G 2.4 mil units IM x 1 dose
 
 Late Latent (>1 year) or unknown duration
 Benzathine Pen G 2.4 mil units IM Qweek x 3 weeks
 
 Neurosyphilis
 -Aqueous crystalline Pen G 18-24 million units IV QD (can be intermittent or continuous infusion) x 10-14 days
 -Aqueous cystalline Pen G 2.4 mil units IM daily + probenecid 500 mg PO QID x 10-14 days
 
 Pen-allergic patients
 Doxy 100 mg PO BID x 14 (x 28 in late latent)
 Tetra 500 mg QID x14 (x28 in late latent)
 Ceftriaxone 1 gm IM/IV QD x 8-19 days (only <1 yr disease)
 |  | 
        |  | 
        
        | Term 
 
        | What is the Jarisch-Herxheimer reaction and with what treatment is it notorious for occurring? |  | Definition 
 
        | Acute syndrome of flu-like symptoms within 24 hours of penicillin treatment (seen with syphilis tx) -Fever, HA, myalgia, tachycardia, flushing, increased respiratory rate
 
 Due to endotoxin release/cytokine cascade
 
 Tx: supportive care, bed rest, NSAIDs
 -self limiting
 |  | 
        |  | 
        
        | Term 
 
        | Which is worse: the first episode or the recurrent episodes of genital herpes simplex virus? |  | Definition 
 
        | First episode: painful ulcers with flu-like sx 
 Recurrent episodes are usually milder and shorter + have a prodrome in ~50% of cases so can get treated sooner
 |  | 
        |  | 
        
        | Term 
 
        | Genital Herpes is most commonly caused bu HSV-1 or HSV-2 |  | Definition 
 
        | HSV-2 
 NOTE: this is also the strain that is more likely to cause recurrent infections
 |  | 
        |  | 
        
        | Term 
 
        | What is a major advantage of treating genital herpes recurrences? |  | Definition 
 
        | Reduce viral shedding which limits the risk of transmission 
 Maximal benefit when treatment is initiated early-management of symptoms
 |  | 
        |  | 
        
        | Term 
 
        | What are two possible treatment regimens for herpes? |  | Definition 
 
        | Treating each episode on a case by case basis 
 Continual long-term suppressive therapy (good for more severe)
 |  | 
        |  | 
        
        | Term 
 
        | Agents use to treat herpes episodically |  | Definition 
 
        | Acyclovir 400 TID x 7-10 Acyclovir 200 5xdaily x 7-10
 Famciclovir 250 TID x 7-10
 Valcyclovir 1 g BID x 7-10
 
 If recurrent episode - use same drugs but usually only require treatment for 5 days
 |  | 
        |  | 
        
        | Term 
 
        | Options for long-term suppressive therapy for herpes |  | Definition 
 
        | Acyclovir 400 BID Famciclovir 250 BID
 Valcyclovir 500 or 1 g QD
 |  | 
        |  | 
        
        | Term 
 
        | How do you treat a severe herpes infection |  | Definition 
 
        | Acyclovir 5-10 mg/kg IV Q8H x2-7 days or until improvement 
 Follow up with PO therapy to complete a 10 day regimen (can go up to 14 days, or until improvement)
 |  | 
        |  | 
        
        | Term 
 
        | If someone presents with deafness and confusion, which STD would you suspect they have? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are two instances when you want to always was to desensitize |  | Definition 
 
        | 1. Necrotizing facitis 2. Tertiary syphilis
 
 Both with penicillin
 |  | 
        |  | 
        
        | Term 
 
        | C. diff is most commonly transmitted how? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which antibiotic is associated with a high prevalence of C.diff diarrhea? |  | Definition 
 
        | Clindamycin 
 
 Others: FQ, 3rd/4th gen Ceph, broad-spectrum Pen
 |  | 
        |  | 
        
        | Term 
 
        | What is the first line treatment for C.diff diarrhea? |  | Definition 
 
        | Vancomycin 125 mg PO Q6h 
 remember: never IV for GI vanc
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | G+ spore forming anaerobe 
 endotoxins: detected by PCR
 Toxin A (TcdA): osmotic changes/secretions
 Toxin B (TcdB): mucosal damage/inflammation
 |  | 
        |  | 
        
        | Term 
 
        | Symptoms of C.diff diarrhea |  | Definition 
 
        | watery diarrhea abdominal pain
 nausea
 leukocytosis
 fever
 |  | 
        |  | 
        
        | Term 
 
        | Risk factors for C.diff diarrhea |  | Definition 
 
        | *Antibiotic use *Contact with C.diff spores
 *Gastric acid suppression (PPIs)
 Advanced age
 Immunosuppresion (Chemo)
 Female gender (unknown why)
 Prolonged hospital/healthcare exposure
 
 * = modifiable
 |  | 
        |  | 
        
        | Term 
 
        | Issues that we are now facing with C.diff treatment |  | Definition 
 
        | Resistance (ex: with FQ) 
 Increased virulence via more toxin production (loss of suppressor gene)
 
 NAP1/BI/027 - resistant strain
 |  | 
        |  | 
        
        | Term 
 
        | What are some non-drug considerations/treatments for C.diff treatment |  | Definition 
 
        | 1. D/c antibiotic if possible 2. Do NOT use antidiarrheal or antiperistaltic (loperamide, metoclopramide)
 3. Do NOT use anion-exchange resin (cholestyramine - binds vancomycin)
 4. Isolate patient with contact precautions
 5. Disinfect hands with SOAP AND WATER (no alcohol sanitizers - cant kill spores)
 |  | 
        |  | 
        
        | Term 
 
        | T or F: When treating for Gonorrhea (either diagnosed or suspected) you should always treat for chlamydia too BUT when you have a diagnosis of Chalmydia you do not have to treat for Gonorrhea. |  | Definition 
 
        | T - if just suspect chlamydia still treat for both, but if you know it is chalmydia, dont have to treat for gonorrhea 
 (refer to discussion board)
 |  | 
        |  | 
        
        | Term 
 
        | What constitutes mild/moderate C.diff infection? 
 What is the treatment?
 |  | Definition 
 
        | WBC<15,000 and SCr<1.5x baseline (normal) 
 Metronidazole 500 mg PO Q8H x10-14 days
 |  | 
        |  | 
        
        | Term 
 
        | What is the treatment of an elderly person with C.diff? |  | Definition 
 
        | Automatically classified as Severe 
 Vancomycin 125 mg PO Q6H x10-14 days
 |  | 
        |  | 
        
        | Term 
 
        | What are the classifications for Severe C.diff diarrhea? 
 What is the treatment?
 |  | Definition 
 
        | WBC>15,000 and SCr >1.5 (inflammation and kidney dysfunction) OR if they are elderly
 
 
 Vancomycin 125 mg PO Q6h x10-14 days
 |  | 
        |  | 
        
        | Term 
 
        | Examples of complicated C.diff infection 
 What is the treatment?
 |  | Definition 
 
        | Hypotension or shock ileus
 megacolon
 
 Vancomycin 500 mg PO or NGtube Q6H AND Metronidazole 500 mg IV Q8H x10-14 days
 
 **If ilues present consider rectal administration of vancomycin
 |  | 
        |  | 
        
        | Term 
 
        | T or F: if you only have IV vancomycin on hand, you can not treat C.diff infection |  | Definition 
 
        | F - the IV formulation can be given PO |  | 
        |  | 
        
        | Term 
 
        | If get a 2nd recurrence of C.diff infection, you should not treat with metronidazole for a 3rd time, why? |  | Definition 
 
        | Potential neurotoxicity (increased risk) 
 peripheral neuropathy
 |  | 
        |  | 
        
        | Term 
 
        | When is metronidazole present in higher concentrations during the treatment of a C.diff infection? |  | Definition 
 
        | At the beginning - higher concentrations found in water diarrhea (as infection improves, concentration of flagyl falls) |  | 
        |  | 
        
        | Term 
 
        | Which is more effective for the treatment of C.diff, vancomycin 125 Q6H or 500 mg Q6h? |  | Definition 
 
        | Both are equally effective - so give 125 mg since probably more tolerable and cheaper 
 (But the 500 mg is seen in practice)
 |  | 
        |  | 
        
        | Term 
 
        | T or F: fecal drug concentrations after PO administration of metronidazole may be reduced in the presence of shock, ileus, or megacolon with a C.diff infection. |  | Definition 
 
        | T - so for complicated  infections give metronidazole IV and vancomycin PO/NG |  | 
        |  | 
        
        | Term 
 
        | What is the most likely cause of C.diff relapse |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is an alternative to vancomycin and metronidazole for C.diff infection |  | Definition 
 
        | Fidaxomicin 
 -macrolide - inhibits RNA polymerase (transcription inactivation)
 -PO, minimal absorption
 -no activity against B.frag or enterococcus (less disruption of normal flora
 
 $$$$ and just as effective as vancomycin
 |  | 
        |  | 
        
        | Term 
 
        | What are some things that can be employed with recurrent C.diff infections? |  | Definition 
 
        | Taper and Pulse vancomycin Supplemental probiotics
 Nitazoxanide
 Adjuvant rifaximin
 Fecal microbiota transplant
 IVIG (iv immunoglobulins)
 |  | 
        |  | 
        
        | Term 
 
        | General outline of vancomycin taper and pulse dosing? 
 Why is it thought to work?
 |  | Definition 
 
        | 1. Taper - start with 125 mg Q6h -->Q12h x7days --> Q24h x 7days 2. Pulse - 125 mg q48h x7 --> Q3days x2-8 weeks
 
 NO vancomycin promotes spores to germinate - then give vanc to kill live cells
 |  | 
        |  | 
        
        | Term 
 
        | When should nitazoxanide be used for a C.diff infection? |  | Definition 
 
        | Approved for diarrhea associated with Cryptosporidia and Giardia 
 Shown to work with metronidazole failure, comparable to vancomycin
 |  | 
        |  | 
        
        | Term 
 
        | When has rifximin been used in C.diff infections? |  | Definition 
 
        | Rifaximin "Chaser" Protocol: give for 2 weeks immediately after completion of last C.diff treatment and before recurrence of symptoms (used to prevent relapse) 
 ONLY USE ONCE - acquired resistance has been seen after initial treatment
 
 Approved for traveler's diarrhea due to noninvasive E.coli
 |  | 
        |  | 
        
        | Term 
 
        | T or F: Treatment with Fecal Microbiota Transplant in not very effective. |  | Definition 
 
        | F - 94-100% cure rate 
 It restores normal flora, reduces drug costs, low technology procedure
 |  | 
        |  | 
        
        | Term 
 
        | T or F: low IgG concentrations are associated with symptom development in patients colonized with C.diff |  | Definition 
 
        | T 
 and IgM is low in patients with repeated recurrences
 |  | 
        |  | 
        
        | Term 
 
        | T or F: IV immunoglobulin administration is a very effective way to treat recurring C.diff infections |  | Definition 
 
        | F - seen to be modestly effective in providing passive immunity in patient with recurrent C.diff infection |  | 
        |  | 
        
        | Term 
 
        | Which is associated with less recurrence of C.diff infections, vancomyin or fidaxomicin? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which beta-lactams cause the worst collateral damage? What do they cause? |  | Definition 
 
        | 3rd generation Ceph (oximinocephalosporins) 
 Cefotaxime, ceftazidime, ceftriaxone
 
 ESBL production
 Selection of stably de-repressed isolates in SPACE bacteria
 Selection of VRE
 Contribution of MRSA emergence
 Increased cases of C.diff associated with diarrhea/colitis
 
 Carbapenems also cause much collateral damage
 |  | 
        |  | 
        
        | Term 
 
        | What is the single most effective measure to prevent spread of resistant organisms |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Core members of the Antimicrobial stewardship team |  | Definition 
 
        | ID physician (director/co-director) Clinical pharmacist with ID training (co-director)
 
 -Microbiologist
 -Information system specialist
 -Infection control professional
 -Hospital epidemiologist
 |  | 
        |  | 
        
        | Term 
 
        | What are the two active core strategies of antimicrobial stewardship? |  | Definition 
 
        | 1. Prospective audit with intervention and feedback to reduce inappropriate antimicrobial use 2. Formulary restriction and pre-authorization leading to reductions in antimicrobial use and cost
 
 Neither is mutually exclusive
 |  | 
        |  | 
        
        | Term 
 
        | What is prospective audit with intervention and feedback |  | Definition 
 
        | When a pharmacist (or someone else) looks at the prescribed ID treatment for a patient. If it is inappropriate, the pharmacist lets the physician know and offers some alternative agents |  | 
        |  | 
        
        | Term 
 
        | What is formulary restriction and pre-authorization? |  | Definition 
 
        | Mechanism of antimicrobial stewardship where the hospital formulary is restricted to several antibiotics and if a prescriber wants to go outside of these antibiotics, they must get authorization |  | 
        |  | 
        
        | Term 
 
        | What are some additional strategies for antimicrobial stewardship apart from prospective audit and formulary restriction with pre-authorization? |  | Definition 
 
        | 1. Educational programs 2. Parenteral to oral conversion
 3. Creation/implementation of guidelines
 4. Antimicrobial order forms
 5. Streamlining/de-escalation (when susceptibilities come back)
 6. Dose optimization (based on PK/PD)
 
 Combination therapy and antimicrobial cycling have insufficient evidence to support their use as stewardship strategies
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | MOA: inhibits cell wall synthesis - binds to substrate (not enzyme like BL) D-ala-D-ala 
 Bactericidal and time dependent
 |  | 
        |  | 
        
        | Term 
 
        | Vancomycin indication restriction (UKCMC) |  | Definition 
 
        | 1. Serious or life threatening infections due to beta-lactam resistant G+ organism 2. Patient with serious beta-lactam allergy 3. PO for colitis that fails metronidazole therapy or if severe 4. Unexplained fever (>101F or 100.4 over 1 hr - PO) in neutropenic patients **Before doing all the calculations make sure vanc in indicated |  | 
        |  | 
        
        | Term 
 
        | Which is a bigger concern with vancomycin, nephrotoxicity or ototoxicity? |  | Definition 
 
        | Nephrotoxicity (increased risk with other nephrotoxic drugs) |  | 
        |  | 
        
        | Term 
 
        | Therapeutic target ranges for vancomycin |  | Definition 
 
        | Trough: 10-20 mg/L Peak: 20-40 mg/L
 
 NOTE: clinically, if trough = 20, then peak will be over 40
 |  | 
        |  | 
        
        | Term 
 
        | Three big ADRs concerning vancomycin (IV) |  | Definition 
 
        | 1. Ototoxicity 2. Nephrotoxicity
 3. Infusion rxn (Red Man's syndrome) - associated with tachycardia, hypotension
 |  | 
        |  | 
        
        | Term 
 
        | If want to premedicate against infusion rxn related to vancomycin what would you give? |  | Definition 
 
        | H2RA or Antihistamine (Benadryl) |  | 
        |  | 
        
        | Term 
 
        | Do you need to adjust the dose of vancomycin if the patient has hepatic failure? |  | Definition 
 
        | No, it is not metabolized 
 only adjust in renal disease
 |  | 
        |  | 
        
        | Term 
 
        | How much time is vancomycin usually infused over? When is the distribution phase assumed to be complete? |  | Definition 
 
        | It is infused over 1 hour (at least). 
 Distribution is assumed to be complete after 2 hours from the start of infusion
 |  | 
        |  | 
        
        | Term 
 
        | T or F: with vancomycin there is a strong correlation between ABW and Vd/Cl |  | Definition 
 
        | T - use ABW in Salazar Corocan Equation for CrCl |  | 
        |  | 
        
        | Term 
 
        | Patients with expected altered vancomycin PK |  | Definition 
 
        | 1. Obese - increased Cl (need bigger doses) 2. Renal failure - decreased Cl
 3. Dialysis - hemodialysis does not significantly remove vancomycin from plasma; high-flux dialysis may remove
 4. Surgery/Critically Ill/Burn - increased Cl (hypermetabolic), high incidence of renal failure
 5. Age - Vd/Cl varies with age; lower doses in elderly
 |  | 
        |  | 
        
        | Term 
 
        | What is the key PK component examined in vancomycin dosing? |  | Definition 
 
        | troughs - at steady state (after 4th dose) 
 minimum of 10 mg/L but 15-20 mg/L for complicated (includes MRSA)
 
 for MIC = 1, target trough >15 mg/L to achieve AUC/MIC = 400
 |  | 
        |  | 
        
        | Term 
 
        | Typical dose of vancomycin? |  | Definition 
 
        | Maintenance: 15-20 mg/kg/dose Q8-12H (with normal renal function) 
 Cap at 2 gm/dose for obese
 
 Loading dose  = 25-30 mg/kg
 |  | 
        |  | 
        
        | Term 
 
        | T or F: you need to monitor peak concentrations to watch for nephrotoxicity in vancomycin |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | T or F: You need to monitor a patient who will be on vancomycin for 2 days |  | Definition 
 
        | F - only if taking for 3+ days |  | 
        |  | 
        
        | Term 
 
        | What is the definition of nephrotoxicity with vancomycin? |  | Definition 
 
        | An increase in SCr of 0.5 mg/dL or >50% increase from baseline, whichever is greater AFTER SEVERAL DAYS of vancomycin (if just 48 hr prob not due to vanco) |  | 
        |  | 
        
        | Term 
 
        | When should you monitor for ototoxicty with vancomycin |  | Definition 
 
        | When it is given with other ototoxic drugs, not with monotherapy |  | 
        |  | 
        
        | Term 
 
        | T or F: vancomycin monitoring is required for therapy with target troughs under 15 mg/L |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How often should you monitor vancomycin levels in hemodynamically unstable patients? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | In general, what is the dosing change required for Pediatrics with vancomycin and why? |  | Definition 
 
        | They have larger volumes of distribution, but kidneys arent working all the way - so give a higher dose and extend the interval |  | 
        |  | 
        
        | Term 
 
        | How often should you draw a vancomycin level for uncomplicated and complicated patients? |  | Definition 
 
        | Uncomplicated - once every 2 weeks Complicated - once every week
 |  | 
        |  | 
        
        | Term 
 
        | What other labs should be monitored with vancomycin therapy |  | Definition 
 
        | Scr and BUN twice weekly (if complicated Q48H) |  | 
        |  | 
        
        | Term 
 
        | T or F: you should always obtain a vancomycin trough for obese patients? |  | Definition 
 
        | T - considered to have altered Cl |  | 
        |  | 
        
        | Term 
 
        | T or F: you always need to monitor vancomycin troughs when treating pneumonia? |  | Definition 
 
        | T - considered life threatening/need higher doses to penetrate to site (meningitis, endocarditis, pneumonia, sepsis, osteomyelitis)
 |  | 
        |  | 
        
        | Term 
 
        | What are the three types of osteomyelitis |  | Definition 
 
        | 1. Hematogenous: non-injury/mainly kids 2. Contiguous: injury-caused
 3. Peripheral Vascular Disease
 |  | 
        |  | 
        
        | Term 
 
        | Which type of osteomyelitis is most common in children? |  | Definition 
 
        | Hematogenous 
 hair-pen turns in bones
 |  | 
        |  | 
        
        | Term 
 
        | Is osteomyelitis acute or chronic? |  | Definition 
 
        | Can be either 
 Chronic if over 1 week
 |  | 
        |  | 
        
        | Term 
 
        | If an adult has hematogenous osteomyelitis, where is it most likely to have occurred? |  | Definition 
 
        | Vertebrae (small hairpin turns in these bones) |  | 
        |  | 
        
        | Term 
 
        | Symptoms associated with osteomyelitis |  | Definition 
 
        | Local: tenderness, swelling, pain 
 Systemic: fever, chills, malaise, decreased ROM (will always be present, but less prevalent in diabetic foot ulcer)
 |  | 
        |  | 
        
        | Term 
 
        | What labs should be obtained if osteomyelitis is suspected? |  | Definition 
 
        | Culture from bone aspirate Culture potential sources (ex: if wound)
 Blood culture
 
 bone scan - can show disease in 1 day
 Radiograph - not seen until day 14 of infection (still always get)
 
 **do an MRI if vascular insufficient osteomyelitis (dye cant get to site easily) instead of bone scan
 |  | 
        |  | 
        
        | Term 
 
        | If a patient suspected of having osteomyelitis gets a radiograph and the results are negative, does it mean they dont have osteomyelitis? |  | Definition 
 
        | Not necessarily - radiograph wont be useful until day 14 of infection. |  | 
        |  | 
        
        | Term 
 
        | What is one of the most important things to look at when deciding what to treat with for osteomyelitis? |  | Definition 
 
        | Bone culture! always get one! |  | 
        |  | 
        
        | Term 
 
        | Mechanism of the development of hematogenous osteomyelitis |  | Definition 
 
        | Kids or vertebral = small bones 
 Slowed blood flow through hairpin turns of vasculature at growth plate
 -Cause avascular necrosis, infection, exudate in bone
 
 over 50% have positive bone culture
 |  | 
        |  | 
        
        | Term 
 
        | Pathogens of hematogenous osteomyelitis? |  | Definition 
 
        | Biggest cause: S.aureus Other in kids: H.flu, S.pyogenes (neonates)
 Other in Adults: E.coli, M.tb
 
 IV  drug users: G-, often in combination (Pseudomonas)
 Sickle Cell: Salmonella (S.aureus, G-)
 |  | 
        |  | 
        
        | Term 
 
        | What is the greatest cause of hematogenous osteomyelitis is people with sickle cell? |  | Definition 
 
        | Salmonella - from GI tract |  | 
        |  | 
        
        | Term 
 
        | What agent is incorporated into any empiric treatment of hematogenous osteomyelitis? |  | Definition 
 
        | Vancomycin (because Staph is most prevalent) 
 Also include Cefepime/3rd gen Ceph if G- on gram stain (H.flu, E.coli)
 
 Alternatives: bactrim or linezolid
 |  | 
        |  | 
        
        | Term 
 
        | What drug should be used to treat hematogenous osteomyelitis in sickle cell patients? |  | Definition 
 
        | Usually cipro or levofloxacin (Cover salmonella) |  | 
        |  | 
        
        | Term 
 
        | What is the most common pathogen in contiguous osteomyelitis? |  | Definition 
 
        | S. aureus (remember, common on skin and this type is caused by an injury) |  | 
        |  | 
        
        | Term 
 
        | What are typical pathogens in contiguous osteomyelitis? |  | Definition 
 
        | S. aureus Strep, S.epidermidis
 PEcK, Pseudomonas
 Anaerobes
 
 Usually multiple organisms if vascular insufficiency (+ enterococcus risk)
 |  | 
        |  | 
        
        | Term 
 
        | What is the gold standard in imaging for suspected osteomyelitis in diabetic foot infections? |  | Definition 
 
        | MRI (bone scan if contraindicated/unavailable) |  | 
        |  | 
        
        | Term 
 
        | Is recurrence common in osteomyelitis? 
 What is recurrence associated with for osteomyelitis?
 |  | Definition 
 
        | YES! major problem (~30%) 
 Correlated with Pseudomonas and use of vancomycin for Staph aureus
 |  | 
        |  | 
        
        | Term 
 
        | What are two critical dosing considerations when treating osteomyelitis? |  | Definition 
 
        | 1. Must use HIGH doses to get a high enough concentration in bone (can use impregnanted bone cement/spacers) 2. Adequate duration:
 -1-3 weeks: if no residual infected bone
 -4-6 weeks: if there is some residual infected bone
 -over 3 months: if no surgery
 |  | 
        |  | 
        
        | Term 
 
        | When can oral therapy be used, specifically in osteomyelitis? |  | Definition 
 
        | When compliance can be ensured When good response to IV therapy
 |  | 
        |  | 
        
        | Term 
 
        | Treatment of osteomyelitis with vascular insufficiency? |  | Definition 
 
        | Treat like diabetic foot: -go by the severity classifications for DFI
 -must cover staph! (not necessarily MRSA)
 -consider covering anaerobes if deep (zosyn, metronidazole, aug)
 |  | 
        |  | 
        
        | Term 
 
        | Empiric therapy for contiguous osteomyelitis without vascular insufficiency |  | Definition 
 
        | Foot bone: Levofloxacin OR Cefepime +/- Vancomycin (covers G- and G+) 
 Long Bone: Vancomycin OR Linezolid + cefepime (DEF COVERING MRSA)
 |  | 
        |  | 
        
        | Term 
 
        | In general, recent antibiotics use increases the chance of what kind of pathogen causing the infection? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | interfere with protein synthesis by binding to ribososmal subunits 
 bactericidal, concentration-dependent killing with post-antibiotic effect
 |  | 
        |  | 
        
        | Term 
 
        | Indications for aminoglycosides |  | Definition 
 
        | aerobic gram-negative bacilli SPACE
 
 typically used for synergy with beta-lactams
 
 different dosages for G- (target therapy) or G+ (synergy)
 |  | 
        |  | 
        
        | Term 
 
        | Which toxicity associated with aminoglycosides is reversible/irreversible |  | Definition 
 
        | nephrotoxicity = reversible ototoxicity = irreversible
 |  | 
        |  | 
        
        | Term 
 
        | Ways to minimize aminoglycoside toxicity |  | Definition 
 
        | -limit total cumulative dose -use alternative drugs if available for high risk patients/sensitivities known
 -monitor renal function tests
 -avoid volume depletion
 -avoid concomitant nephrotoxic/ototoxic drugs
 -PK monitoring/dosing
 -QD dosing might be better (maybe)
 |  | 
        |  | 
        
        | Term 
 
        | How long is the distribution phase for aminoglycosides? |  | Definition 
 
        | Conventional dosing: 1 hour after start of infusion Once-Daily Dosing: 2 hours
 |  | 
        |  | 
        
        | Term 
 
        | Normal half-life of aminoglycosides |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is renal function monitored when a patient is on an aminioglycoside? How often? |  | Definition 
 
        | SCr/BUN are measured 
 at least twice weekly
 
 Monitor other signs too
 |  | 
        |  | 
        
        | Term 
 
        | How often should a peak and trough be drawn and measured when a patient is on aminoglycoside therapy (>2 weeks) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | T or F: the peritoneum is usually a sterile space |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the three classes of peritonitis? |  | Definition 
 
        | Primary: spontaneous, unidentified sourse (common in alcoholics) Secondary: perforation in GI tract, uterus, or urinary tract INJURY
 Tertiary: persistent or recurrent infection after surgery or antimicrobial therapy
 |  | 
        |  | 
        
        | Term 
 
        | If there is peritonitis due to colon perforation, what must be covered? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the two types of primary peritonitis? |  | Definition 
 
        | 1. Cirrhotic Origin 2. Dialysis origin |  | 
        |  | 
        
        | Term 
 
        | What are the usual organisms for the two types of primary peritonitis? |  | Definition 
 
        | Cirrhotic: -E.coli (*) -Klebsiella -Strep   Dialysis (from skin/plastic) -Staph (*) -Strep -Some enteric G- |  | 
        |  | 
        
        | Term 
 
        | What is a good therapeutic option for treatment of cirrhotic peritonitis? |  | Definition 
 
        | Ceftriaxone (covers E.coli, Klebsiella, Strep) x 5-10 days |  | 
        |  | 
        
        | Term 
 
        | Which do you treat longer, cirrhotic or dialysis caused primary peritonitis? |  | Definition 
 
        | Dialysis (10-14 days) [cirrhotic = 5-10 days] |  | 
        |  | 
        
        | Term 
 
        | Which carbapenem doesnt cover pseudomonas? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Possible antimicrobial regimens for healthcare-associated infections (intraabdominal infection) |  | Definition 
 
        | Zosyn Antipseudomonal carbapenems (all but Erta) 3rd/4th gen Ceph + metronidazole FQ + metronidazole   Pseudomonas and Anaerobes |  | 
        |  | 
        
        | Term 
 
        | Candida is often cultured with intraabdominal infections, should it be treated? |  | Definition 
 
        | Not usually, unless immunosuppressed |  | 
        |  | 
        
        | Term 
 
        | When should you cover enterococcus in peritonitis? |  | Definition 
 
        | NOT for most community-acquired peritonitis Cover if patient has VRE or are immunocompromised
 |  | 
        |  | 
        
        | Term 
 
        | Does zosyn or ceftriaxone cover psuedomonas? |  | Definition 
 
        | zosyn does ceftrixaone does not cover Pseudomonas
 |  | 
        |  | 
        
        | Term 
 
        | What antibiotics cover anaerobes |  | Definition 
 
        | metronidazole Tigecycline
 Zosyn
 |  | 
        |  | 
        
        | Term 
 
        | How would Aspergillus be described by the lab? |  | Definition 
 
        | Septate hyphae Conidia/spores
 
 flat,velvety consistancy
 |  | 
        |  | 
        
        | Term 
 
        | What does hyaline hyphae mean? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What does dematiaceous fungi mean? |  | Definition 
 
        | pigmented fungi (produce melainin) brown or black coloring
 |  | 
        |  | 
        
        | Term 
 
        | What type of patients are fungal infections commonly seen in? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How would the lab describe Zygomycetes? |  | Definition 
 
        | Aseptate hyphae Rapid growth (compared to Aspergillus)
 Sporangium formation (sac-like structure containing spores)
 |  | 
        |  | 
        
        | Term 
 
        | What two types of dimorphic fungi do we need to be concerned with Kentucky? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How are dimorphic fungi usually transmitted? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Dimorphic fungi can be either mould-like or yeast-like, what environmental conditions decide this? |  | Definition 
 
        | At environmental temps: mould 
 At body temps: yeast
 |  | 
        |  | 
        
        | Term 
 
        | What advantage did the lipid formulations of Amphotericin B have over the original formulation? |  | Definition 
 
        | They are equally effective, they are less toxic |  | 
        |  | 
        
        | Term 
 
        | What is itraconazole used for (DOC) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What patients still use conventional amphotericin B? |  | Definition 
 
        | Only dialysis patients (because lipid formulations are expensive and their kidneys are already dying) |  | 
        |  | 
        
        | Term 
 
        | Which antifungal has the broadest spectrum of activity? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the DOC for Aspergillus? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What toxicities are associated with Amphotericin B? |  | Definition 
 
        | nephrotoxicity (70% of people taking the conventional form) - less with kids 
 infusion-related toxicity: slow it down (fever, chills, rigors, N/V, myalgias)
 |  | 
        |  | 
        
        | Term 
 
        | How is the infusion-related toxicity of Amp B managed? |  | Definition 
 
        | Low-dose corticosteroids APAP
 Meperidine (rigors)
 |  | 
        |  | 
        
        | Term 
 
        | How is the nephrotoxicity of Amp B managed? |  | Definition 
 
        | Hydration/salt loading USE LIPID PRODUCT
 |  | 
        |  | 
        
        | Term 
 
        | MOA of Amp B compared to Azoles |  | Definition 
 
        | Amp B: binds to ergosterol and creates pore in membrane 
 Azoles: prevents synthesis of ergosterol
 
 Both at high doses will start to target cholesterol too--not seen with echinocandins because they target cell wall, which humans dont have
 |  | 
        |  | 
        
        | Term 
 
        | What is the conventional dose and lethal dose of Amp B? What is the liposomal dose? |  | Definition 
 
        | Conventional: 0.5-1 mg/kg Lethal Dose: 3 mg/kg
 
 Liposomal Dose: 3-5 mg/kg
 |  | 
        |  | 
        
        | Term 
 
        | What is fluconazole DOC for? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Spectrum of activity of fluconazole |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the dosage forms of itraconazole? |  | Definition 
 
        | Solution: empty stomach and tastes bad Capsule: FATTY meal in acidic environment
 |  | 
        |  | 
        
        | Term 
 
        | When on itraconazole, do you need to monitor kidney or liver function? |  | Definition 
 
        | BOTH 
 Renal - cyclodextrine is the solvent used and is toxic to kidney
 
 Hepatic - BIG drug interactions (3A4)
 |  | 
        |  | 
        
        | Term 
 
        | Which anti-fungal has the WORST drug interaction profile? |  | Definition 
 
        | Voriconazole 
 substrate and inhibitor of 3A4, 2C9, 2C19
 |  | 
        |  | 
        
        | Term 
 
        | When on voriconazole what should be monitored? (kidney?Hepatic?) |  | Definition 
 
        | BOTH 
 Kidney: cyclodextrin solvent (can cause multiorgan failure); contraindicated in renal failure
 
 Hepatic: BIG DRUG INTERACTIONS
 |  | 
        |  | 
        
        | Term 
 
        | What is the dosage form of posaconazole and how is it administered? |  | Definition 
 
        | Oral solution 
 MUST be taken with high fat meal (50g) BID-QID
 |  | 
        |  | 
        
        | Term 
 
        | What is posaconazole used for? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Spectrum of activity of echinocandins? |  | Definition 
 
        | Aspergillus Candida
 
 (fairly narrow spectrum)
 |  | 
        |  | 
        
        | Term 
 
        | What are some echinocandins? |  | Definition 
 
        | Micafungin Capsofungin
 Anidulafungin
 |  | 
        |  | 
        
        | Term 
 
        | Toxicities associated with echinocandins? |  | Definition 
 
        | none, very low toxicity -very safe |  | 
        |  | 
        
        | Term 
 
        | What drug is typically added as a second agent in fungal infections to enhance efficacy? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the three 'recipes' for AIDS therapy? |  | Definition 
 
        | 2 NRTI + 1 NNRTI 2 NRTI + 1 PI
 2 NRTI + 1 II
 
 **if not on one of these regimens, the the patient probably has resistance**
 |  | 
        |  | 
        
        | Term 
 
        | What antibiotics cover Pseudomonas? |  | Definition 
 
        | Pip/Tazo Ceftazidime
 Cefepime
 Imipenem/Meropenem
 Aztreonam
 Aminoglycosides (in combo)
 |  | 
        |  | 
        
        | Term 
 
        | What antibiotics have anaerobic coverage |  | Definition 
 
        | Metronidazole Tigecycline
 Beta-lactam + beta-lactamase inhibitors (ie Pip/Tazo, Amp/Sul, Amox/Clav)
 Cefoxitin
 Carbapenems
 Moxifloxacin
 PO Vanco (C.diff)
 |  | 
        |  |